Prepping for PhIII cancer study, Sellas reverse merges its way to a public listing
With its one and only cancer drug poised to start a Phase III study sometime later this year, Sellas is getting into the public market …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
